Warfarin 2.5 mg Daily – Monitoring, Dose Adjustment, and Management of Abnormal INR

Monitoring Frequency

• Initiation vs. maintenance monitoring – The therapeutic phase (initiation or stable maintenance) determines how often INR should be checked; patients in the initiation phase require more frequent testing, whereas those on stable maintenance can be monitored every 4–12 weeks. [American College of Chest Physicians] 1
• Interval selection – The exact monitoring interval should reflect the duration of prior INR stability and any anticipated changes in medications or clinical status. [American College of Chest Physicians] 1

Determining Bleeding Risk

• Key bleeding risk factors – Age ≥ 65 years, prior stroke or gastrointestinal bleeding, renal insufficiency, anemia, and concurrent antiplatelet therapy increase the risk of bleeding and influence INR‑related management decisions. [American College of Cardiology] 2

Sub‑Therapeutic INR Management

• Mildly sub‑therapeutic (≤ 0.5 below target) in a previously stable patient – Continue the current 2.5 mg dose, repeat INR in 1–2 weeks, and do not initiate bridging therapy unless the patient has a mechanical heart valve. [American College of Chest Physicians] 1

Supratherapeutic INR Management

INR < 5.0 without bleeding

• Dose modification – Reduce the daily dose or omit the next dose; resume warfarin at a lower dose once INR returns to the therapeutic range. [American College of Cardiology] [3][4]5

INR 5.0–9.0 without high bleeding risk

• Withholding warfarin – Omit the next 1–2 doses; restart at a lower dose when INR falls within the therapeutic window. [American College of Cardiology] [3][4][5][6]7

INR 5.0–9.0 with increased bleeding risk

• Oral vitamin K₁ – Omit the next dose and give oral vitamin K₁ 1–2.5 mg; this lowers INR to < 5 within 24 hours more rapidly than withholding warfarin alone. [American College of Cardiology] [3][4][5][6][7][8]
• Safety of oral route – Oral vitamin K₁ is safer than intravenous (which can cause anaphylaxis) and provides more predictable absorption than subcutaneous administration. [American College of Cardiology] [3][5][6][7]

INR ≥ 9.0 without bleeding

• Oral vitamin K₁ dosing – Administer oral vitamin K₁ 3–5 mg; INR typically falls within 24–48 hours, with close INR monitoring and repeat dosing as needed. [American College of Cardiology] [3][4][5][6][7][8]

INR ≥ 9.0 with serious bleeding or INR ≥ 20

• Intravenous vitamin K₁ – Give vitamin K₁ 10 mg by slow IV infusion over 30 minutes. [American College of Cardiology] [3][4][5][6][7][8]
• Adjunctive hemostatic therapy – Administer fresh frozen plasma or prothrombin complex concentrate to rapidly correct coagulopathy. [American College of Cardiology] [3][4][5][6][7][8]
• Repeat dosing – Additional 10 mg IV vitamin K₁ doses may be required every 12 hours until INR is safely reduced. [American College of Cardiology] [6][8]

Vitamin K Administration Considerations

• Avoid high‑dose oral vitamin K (10 mg) for non‑emergent situations – Such dosing can induce warfarin resistance lasting up to one week and may overshoot the desired INR correction. [American College of Cardiology] [3][4][5][6][7][8]
• Subcutaneous vitamin K is not recommended – Absorption is unpredictable and may be delayed, making it unsuitable for rapid INR correction. [American College of Cardiology] [3][5][6][7]8

Practical Pitfalls

• Do not adjust dose for isolated INR values that are only 0.5 units outside the therapeutic range in a patient with prior stability – Unnecessary adjustments can cause dose cycling and INR instability. [American College of Chest Physicians] 1
• After any dose change, increase monitoring frequency until a consistent pattern of stable therapeutic INRs is re‑established. [American College of Chest Physicians] 1

Strength of evidence: not explicitly stated in the source material.